OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis

Cross, 2014, The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study, Ann Rheum Dis, 73, 1323, 10.1136/annrheumdis-2013-204763

Hermans, 2012, Productivity costs and medical costs among working patients with knee osteoarthritis, Arthritis Care Res (Hoboken)., 64, 853, 10.1002/acr.21617

Hunter, 2014, The individual and socioeconomic impact of osteoarthritis, vol. 10, 437

Le Pen, 2005, Financial cost of osteoarthritis in France. The "COART" France study, Jt Bone Spine, 72, 567, 10.1016/j.jbspin.2005.01.011

Kingsbury, 2014, Osteoarthritis in Europe: impact on health status, work productivity and use of pharmacotherapies in five European countries, Rheumatology (Oxford), 53, 937, 10.1093/rheumatology/ket463

Sharif, 2017, Productivity costs of work loss associated with osteoarthritis in Canada from 2010 to 2031, Osteoarthritis Cartilage, 25, 249, 10.1016/j.joca.2016.09.011

McAlindon, 2014, OARSI guidelines for the non-surgical management of knee osteoarthritis, Osteoarthr Cartil/OARS, 22, 363, 10.1016/j.joca.2014.01.003

Zhang, 2008, OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines, Osteoarthritis Cartilage, 16, 137, 10.1016/j.joca.2007.12.013

Guyatt, 2008, GRADE: an emerging consensus on rating quality of evidence and strength of recommendations, Bmj, 336, 924, 10.1136/bmj.39489.470347.AD

Guyatt, 2011, GRADE guidelines: 2. Framing the question and deciding on important outcomes, J Clin Epidemiol, 64, 395, 10.1016/j.jclinepi.2010.09.012

The Cochrane Collaboration. RevMan 5.3. http://tech.cochrane.org/revman.

The Cochrane Collaboration. The Cochrane risk of bias tool. http://handbook.cochrane.org.

DerSimonian, 1986, Meta-analysis in clinical trials, Contr Clin Trials, 7, 177, 10.1016/0197-2456(86)90046-2

Mantel, 1959, Statistical aspects of the analysis of data from retrospective studies of disease, J Natl Cancer Inst, 22, 719

Higgins, 2002, Quantifying heterogeneity in a meta-analysis, Stat Med, 21, 1539, 10.1002/sim.1186

Rucker, 2008, Undue reliance on I(2) in assessing heterogeneity may mislead, BMC Med Res Methodol, 8, 79, 10.1186/1471-2288-8-79

Evidence Prime, 2015

Andrews, 2013, GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations, J Clin Epidemiol, 66, 719, 10.1016/j.jclinepi.2012.03.013

Andrews, 2013, GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength, J Clin Epidemiol, 66, 726, 10.1016/j.jclinepi.2013.02.003

Nissen, 2016, Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis, N Engl J Med, 375, 2519, 10.1056/NEJMoa1611593

Trelle, 2011, Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis, BMJ, 342, c7086, 10.1136/bmj.c7086

Mukherjee, 2001, Risk of cardiovascular events associated with selective COX-2 inhibitors, Jama, 286, 954, 10.1001/jama.286.8.954

Bally, 2017, Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data, Bmj, 357, j1909, 10.1136/bmj.j1909

Underwood, 2008, Topical or oral ibuprofen for chronic knee pain in older people. The TOIB study, Health Technol Assess, 12, 10.3310/hta12220

Deveza, 2018, Too much opioid, too much harm, Osteoarthritis Cartilage, 26, 293, 10.1016/j.joca.2017.12.003

Jeffery, 2018, Trends in opioid use in commercially insured and Medicare Advantage populations in 2007-16: retrospective cohort study, Bmj, 362, k2833, 10.1136/bmj.k2833

Inacio, 2018, Prevalence and changes in analgesic medication utilisation 1 year prior to total joint replacement in an older cohort of patients, Osteoarthritis Cartilage, 26, 356, 10.1016/j.joca.2017.11.016

Birke, 2016, Chronic non-cancer pain and the epidemic prescription of opioids in the Danish population: trends from 2000 to 2013, Acta Anaesthesiol Scand, 60, 623, 10.1111/aas.12700

Volkow, 2016, Opioid abuse in chronic pain--misconceptions and mitigation strategies, N Engl J Med, 374, 1253, 10.1056/NEJMra1507771

Vowles, 2015, Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis, Pain, 156, 569, 10.1097/01.j.pain.0000460357.01998.f1

da Costa, 2014, Oral or transdermal opioids for osteoarthritis of the knee or hip, Cochrane Database Syst Rev

Krebs, 2018, Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE randomized clinical trial, Jama, 319, 872, 10.1001/jama.2018.0899

Smith, 2016, Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review, Osteoarthritis Cartilage, 24, 962, 10.1016/j.joca.2016.01.135

Barcella, 2019, Differences in cardiovascular safety with non-steroidal anti-inflammatory drug therapy—a nationwide study in patients with osteoarthritis, Basic Clin Pharmacol Toxicol, 124, 629, 10.1111/bcpt.13182

Bhala, 2013, Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials, Lancet, 382, 769, 10.1016/S0140-6736(13)60900-9

Solomon, 2018, Differences in safety of nonsteroidal antiinflammatory drugs in patients with osteoarthritis and patients with rheumatoid arthritis: a randomized clinical trial, Arthritis Rheum, 70, 537, 10.1002/art.40400

da Costa, 2017, Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis, Lancet, 390, e21, 10.1016/S0140-6736(17)31744-0

Hochberg, 2015, Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies, Osteoarthritis Cartilage, 23, S18, 10.1016/j.joca.2014.10.005

Cohen, 1988, Statistical power analysis for the behavioral sciences